Access Official Technical PDF

Share Summary:LinkedInEmail

Olympus’ 2019 global medtech strategy set out a significant shift in how the company planned to grow: sharpen its focus on medical technology, build on its position in endoscopy and improve the organizational capabilities needed to compete as a global business. For industrial automation and technology leaders, the strategy offers a useful example of how a company with a broad technical heritage can realign its portfolio, operating model and investment priorities around a core market.

Olympus entered its second century with businesses spanning medical, scientific and imaging products. The medical field already accounted for approximately 80% of revenue, while the company identified opportunities to improve decision speed, efficiency and profitability. Its transformation plan, Transform Olympus, connected those operational changes with a longer-term ambition to become a globally leading medtech company.

Global medtech strategy: focus the portfolio and clarify accountability

A central premise of the strategy was that a strong market position alone would not guarantee future growth. Olympus recognized the need to respond faster to changing market conditions, regulatory requirements and customer needs. It therefore proposed concentrating the corporate portfolio around medical technology while defining clearer responsibilities across global operations.

The company moved toward centralized global group management, with an executive team responsible for companywide strategy and plans. Business and function leaders received clearer accountability for execution. The intended result was a more direct connection between strategic decisions and operational action, reducing ambiguity over who was responsible for delivering priorities.

Organizational changes also included globally integrated human resources management and a transition to a three-committee board structure. Olympus said these measures were intended to support faster decision-making, strengthen governance and make board oversight more focused on strategy and management performance. For any complex technology business, this illustrates an important point: portfolio focus is difficult to execute without corresponding changes to decision rights, talent practices and governance.

Strengthen endoscopy while expanding therapeutic solutions

Olympus identified two complementary priorities within its medical business. The Endoscopic Solutions Division would reinforce the company’s position in reusable endoscopes, while the Therapeutic Solutions Division would focus on selected areas with growth potential, including gastrointestinal endotherapy, urology and respiratory endotherapy.

Build on reusable endoscope leadership

For endoscopy, the strategy emphasized continued product innovation and commercial execution. Olympus planned to develop technologies supporting the detection, characterization, staging and treatment of lesions. It also aimed to evolve the commercial model beyond equipment sales toward services and offerings linked to medical procedures.

The report highlighted maintenance and reprocessing services, including cleaning, disinfection and sterilization, as areas for pilot programs. It also described trials of evidence- or procedure-based payment models for selected products and regions. These initiatives reflect an effort to connect the value proposition more closely to clinical use and ongoing service requirements.

Develop a broader therapeutic portfolio

In therapeutic devices, Olympus planned to concentrate resources on areas where it believed it could build stronger positions. The company had established a global headquarters for the Therapeutic Solutions Division in the United States, aiming to strengthen access to customers and relevant industry capabilities. Its plans included expanding products and procedures, pursuing concurrent product development and reinforcing regulatory and clinical affairs functions.

The strategy also included adding single-use endoscopes to complement reusable products. Olympus described these devices as relevant in situations requiring convenient preparation and infection control, and noted development work for the duodenum, biliary duct and urinary tract. The intention was not to replace reusable systems outright, but to broaden the portfolio to address different clinical requirements.

Improve operating efficiency and financial visibility

Transform Olympus treated profitability and capital efficiency as essential to sustainable growth. The company identified cost containment, better resource allocation and stronger financial monitoring as priorities. Its CFO described “visualization” of business performance as extending beyond revenue and profit to include product costs, selling, general and administrative expenses, research and development, inventory and capital investment.

This approach supports a more complete view of how resources are being used across a business. When operating data and financial measures are considered together, leaders can better assess whether investment is translating into performance and where changes may be needed. Olympus also emphasized using financial indicators to evaluate both growth and the efficiency of the capital employed in each business.

The 2019 strategy set an ambition to reach an operating margin of at least 20% over the medium term, alongside goals for free cash flow growth, return on invested capital and earnings per share growth. These were stated corporate targets, not results already achieved. The company’s plan was to first improve profitability and efficiency, then use the resulting capacity to support growth investments and other strategic priorities.

Build capabilities for regulated, customer-focused growth

Olympus recognized that expansion in medical technology depends on more than product engineering. It identified the need to strengthen medical affairs, quality and regulatory capabilities as requirements for supporting business growth and providing safe, high-quality products. The company also planned to shift its approach to customer value toward greater use of medical evidence and data, alongside product features and technical expertise.

In parallel, the transformation called for a corporate culture emphasizing customer focus, productivity, speed and efficiency. These aims are relevant across industrial sectors: new technology and portfolio decisions create value only when employees, processes and supporting functions are equipped to deliver them consistently.

Practical implications for technology leaders

The Olympus strategy brought together portfolio choices, operating-model changes and financial discipline rather than treating them as separate initiatives. Its practical lessons for technical decision-makers include:

  • Align structure with strategy. Clear ownership and decision rights help translate corporate priorities into execution.
  • Balance core strengths with adjacent needs. Reusable endoscopy remained central, while single-use devices and therapeutic products broadened the offer.
  • Invest in enabling functions. Quality, regulatory, clinical and service capabilities support growth in complex, regulated markets.
  • Make performance visible. Monitoring costs, inventory, R&D and capital investment alongside sales can inform resource decisions.
  • Connect customer value to delivery models. Service and procedure-oriented approaches can complement traditional product offerings.

For plant managers, system integrators and operations leaders, the broader message is that transformation requires operational mechanisms as well as strategic intent. A company must connect its technical portfolio to the way it makes decisions, manages resources and supports customers.

Conclusion

Olympus’ 2019 global medtech strategy aimed to build on endoscopy leadership while expanding therapeutic solutions and improving the efficiency of the organization behind them. Centralized management, clearer accountability, stronger quality and regulatory capabilities, and more disciplined financial visibility were presented as supporting conditions for growth. The practical implication is straightforward: sustainable technology leadership depends not only on innovation, but also on the operating model and organizational capabilities that turn innovation into reliable customer value.

Access Official Technical PDF

About The Author